Comprehensive evaluation of eight commercial SARS-CoV-2 IgG assays

Hönemann, Mario; Lück, Christian; Maier, Melanie; Pietsch, Corinna; Dietze, Nadine; Berthold, T.; Encalada, Marco Vinicio Narvaez; Grünewald, Thomas; Neumeister, Volker; Dalpke, Alexander H.; Liebert, Uwe G.

doi:10.1016/j.diagmicrobio.2021.115382

Cited by 2 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is at least the case for the test systems used here. The S1 IgG antibody kinetic might be different in assays of other manufactures [ 35 ]. Nevertheless according to our data, we propose the use of RBD-IgGAM determination as a rapid and simple surrogate marker to estimate the levels of nAbs after SARS-CoV-2 mRNA vaccination.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2

Nickel

Rockstroh²,

Wolf³

et al. 2022

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Background The currently used SARS-CoV-2 mRNA vaccines have proven to induce a strong and protective immune response. However, functional relevance of vaccine-generated antibodies and their temporal progression are still poorly understood. Thus, the central aim of this study is to gain a better understanding of systemic and mucosal humoral immune response after mRNA vaccination with BNT162b2. Methods We compared antibody production against the S1 subunit and the RBD of the SARS-CoV-2 spike protein in sera of BNT162b2 vaccinees, heterologous ChAdOx1-S/BNT162b2 vaccinees and COVID-19 patients. We monitored the neutralizing humoral response against SARS-CoV-2 wildtype strain and three VOCs over a period of up to eight months after second and after a subsequent third vaccination. Results In comparison to COVID-19 patients, vaccinees showed higher or similar amounts of S1- and RBD-binding antibodies but similar or lower virus neutralizing titers. Antibodies peaked two weeks after the second dose, followed by a decrease three and eight months later. Neutralizing antibodies (nAbs) poorly correlated with S1-IgG levels but strongly with RBD-IgGAM titers. After second vaccination we observed a reduced vaccine-induced neutralizing capacity against VOCs, especially against the Omicron variant. Compared to the nAb levels after the second vaccination, the neutralizing capacity against wildtype strain and VOCs was significantly enhanced after third vaccination. In saliva samples, relevant levels of RBD antibodies were detected in convalescent samples but not in vaccinees. Conclusions Our data demonstrate that BNT162b2 vaccinated individuals generate relevant nAbs titers, which begin to decrease within three months after immunization and show lower neutralizing potential against VOCs as compared to the wildtype strain. Large proportion of vaccine-induced S1-IgG might be non-neutralizing whereas RBD-IgGAM appears to be a good surrogate marker to estimate nAb levels. A third vaccination increases the nAb response. Furthermore, the systemic vaccine does not seem to elicit readily detectable mucosal immunity.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2

Nickel

Rockstroh²,

Wolf³

et al. 2022

PLoS ONE

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, Charlton et al observed that CMIA detecting IgG antibodies against recombined nucleocapsid protein (Abbott) had a higher sensitivity than the anti-spike protein antibody detection assay (DiaSorin) in both negative and positive samples [ 6 ]. On the other hand, Honemann et al observed that assay performance was independent of the usage of either nucleocapsid or spike proteins [ 7 ]. Cerino et al reported good agreement for Abbott (Cohen’s kappa coefficient: 0.69) and moderate agreement for Liaison (Cohen’s kappa coefficient: 0.58); however, their study showed that Abbott and Liaison SARS-CoV-2 CLIA IgG had good agreement in seroprevalence assessment [ 8 ].…”

Section: Discussionmentioning

confidence: 99%

Serology in COVID-19: Comparison of Two Methods

Moniuszko

Jelski

Dunaj

et al. 2021

IJERPH

View full text Add to dashboard Cite

Background: The aim of our study was to examine the performance of two assays in detecting SARS-CoV-2 antibodies. Methods: A total of 127 COVID-19 disease contacts from the Infectious Diseases Department were included. Two serological tests were used: SARS-CoV-2 IgG CMIA on the Alinity system (Abbott) and LIAISON® SARS-CoV-2 S1/S2 IgG CLIA (DiaSorin). Results: The assays exhibited a 96.85% (123/127 patients) test result agreement. In two cases, the positive results obtained by SARS-CoV-2 IgG CMIA on the Alinity system (Abbott) were negative based on the LIAISON® SARS-CoV-2 S1/S2 IgG CLIA (DiaSorin) test, and in two cases, negative results from the LIAISON® SARS-CoV-2 S1/S2 IgG CLIA (DiaSorin) test were positive with the SARS-CoV-2 IgG CMIA on the Alinity system (Abbott). Conclusions: Based on the results of our study, we conclude that in population medicine, the assessments of anti-SARS-CoV-2 antibodies after exposure to SARS-CoV-2 virus based on spike protein or nucleocapsid protein show comparable effectiveness.

show abstract

Comprehensive evaluation of eight commercial SARS-CoV-2 IgG assays

Cited by 2 publications

References 32 publications

Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2

Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2

Serology in COVID-19: Comparison of Two Methods

Contact Info

Product

Resources

About